PGG-Glucan, a soluble β-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-κB-like factor in human PMN: Evidence for a glycosphingolipid β-(1,3)-glucan receptor

Immunopharmacology

Volumn 41, Issue 2, 1999, Pages 89-107

  Wakshull, Eric ^a   Brunke Reese, Deborah ^a   Lindermuth, Johanna ^a   Fisette, Leslie ^a   Nathans, Robin S ^a   Crowley, John J ^b   Tufts, Jeffrey C ^b   Zimmerman, Janet ^a   Mackin, William ^a   Adams, David S ^b  

^a Alpha Beta Technol One Innov Dr ^*  (United States)

^b WORCESTER POLYTECHNIC INSTITUTE   (United States)

Author keywords

glucan; Immunomodulators; Lactosylceramide; Leukocyte priming; Receptors; Signal transduction

Indexed keywords

ACTIGUM; BETA GLUCAN; GLYCOSPHINGOLIPID; IMMUNOMODULATING AGENT; LACTOSYLCERAMIDE; SCLEROGLUCAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; BETA-GLUCANS; BINDING SITES; BLOOD BACTERICIDAL ACTIVITY; CELL MEMBRANE; CYTOKINES; DNA-BINDING PROTEINS; GLUCANS; GLYCOSPHINGOLIPIDS; HUMANS; LACTOSYLCERAMIDES; NEUTROPHILS; NF-KAPPA B; RECEPTORS, IMMUNOLOGIC; RESPIRATORY BURST; SUBSTRATE SPECIFICITY; TRITIUM;

EID: 0032983998     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(98)00059-9     Document Type: Article

References (89)

1. Abel G., Czop J.K. Stimulation of human monocyte β-glucan receptors by glucan particles induces production of TNF-α and IL-1β Int. J. Immunopharmacol. 14:1992;1363-1373.
2. Adams D., Pero S.C., Petro J.B., Nathans R., Mackin W.M., Wakshull E. PGG-Glucan activates NF-κB-like and NF-IL6-like transcription factor complexes in a murine monocytic cell line. J. Leuk. Biol. 62:1997;865-873.
3. Angstrom J., Teneberg S., Milh M.A., Larsson T., Leonardsson I., Olsson B.-M., Halvarsson M.O., Danielsson D., Naslund I., Ljungh A., Wadstrom T., Karlsson K.-A. The lactosylceramide binding specificity of Helicobacter pylori. Glycobiology. 8:1998;297-309.
4. Babineau T.J., Hackford A., Kenler A., Bistrian B., Forse P.A., Fairchild P.G., Heard S., Keroack M., Caushaj P., Benotti P. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-Glucan) in high risk surgical patients. Arch. Surg. 129:1994;1204-1210.
5. Babineau T.J., Marcello P., Swails W., Kenler A., Bistrian B., Forse R.A. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-Glucan) in high-risk surgical patients. Ann. Surg. 220:1994;601-609.
6. Baeuerle P.A., Henkel T. Function and activation of the NF-κB in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
7. Baldwin A.S. The NF-κB and IκB proteins: New discoveries and insights. Annu. Rev. Immunol. 14:1996;649-681.
8. Bhunia A.K., Han H., Snowden A., Chatterjee S. Lactosylceramide stimulates ras-GTP loading, kinases (MEK, Raf), p44 mitogen-activated protein kinase, and c-fos expression in human aortic smooth muscle cells. J. Biol. Chem. 271:1996;10660-10666.
9. Bleicher P., Mackin W. Betafectin® PGG-Glucan: A novel carbohydrate immunomodulator with anti-infective properties. J. Biotechnol. Healthcare. 2:1995;207-222.
10. Bohn J.A., BeMiller J.N. (1→3)-D-glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydrate Polymers. 28:1995;3-14.
11. Boring L., Gosling J., Monteclaro F.S., Lusis A.J., Tsou C.-L., Charo I.F. Molecular cloning and functional expression of murine JE (monocyte chemattractant protein 1) and murine macrophage inflammatory protein 1α receptors. Evidence for two closely linked C-C chemokine receptors on chromosome 9. J. Biol. Chem. 271:1996;7551-7558.
12. Bovin, N.V., 1997. Carbohydrate-carbohydrate interaction. In: Gabius, H.-J., Gabius, S. (Eds.), Glycosciences: Status and Perspectives. Chapman and Hall, pp. 277-289.
13. Cai T.-Q., Wight S.D. Energetics of leukocyte integrin activation. J. Biol. Chem. 270:1995;14358-14365.
14. Cain J.A., Newman S.L., Ross G.D. Role of complement receptor type three and serum opsonins in the PMN response to yeast. Complement. 4:1987;75-86.
15. Castro M., Ralston N.V.C., Morgenthaler T.I., Rohrbach M.S., Limper A.H. Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through α-mannan and β-glucan cell wall components. Infection Immunity. 62:1994;31338-31345.
16. Chen T.-Y., Lei M.-G., Suzuki T., Morrison D.C. Lipopolysaccharide receptors and signal transduction pathways in mononuclear phagocytes. Curr. Topics Microbiol Immunol. 181:1992;169-188.
17. Czop J.K. Phagocytosis of particulate activator of the alternate complement pathway: effects of fibronectin. Advances in Immunol. 38:1986;361-398.
18. Czop J.K., Austen K.F. A β-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J. Immunol. 134:1985;2588-2593.
19. Czop J.K., Gurish M.F., Kadish J.L. Production and isolation of rabbit anti-idiotypic anitbodies directed against the human monocyte receptor for yeast β-glucans. J. Immunol. 145:1990;995-1001.
20. Czop J.K., Kay J. Isolation and characterization of β-glucan receptors on human mononuclear phagocytes. J. Exp. Med. 173:1991;1511-1520.
21. Czop J.K., Puglisi A.V., Miorandi D.Z., Austen K.F. Perturbation of β-glucan receptors on human PMNs initiates phagocytosis and leukotriene B4 production. J. Immunol. 141:1988;3170-3176.
22. Dische Z. Color reactions of carbohydrates. Methods Carbohydr. Chem. 1:1962;478-512.
23. Doita M., Rasmussen L.-T., Seljelid R., Lipsky P.E. Effect of soluble aminated β-1,3-D-polyglucose on human monocytes: stimulation of cytokine and prostaglandin E2 production but not antigen-presenting function. J. Leuk. Biol. 49:1991;342-351.
24. Engstad R.E., Robertsen B. Specificity of a β-glucan receptor on macrophages from Atlantic salmon (Salmo satar L.). Develop. Comp. Immunol. 18:1994;397-408.
25. Ezekowitz R.A., Sastry, Bailly P., Warner A. Molecular characterization of the human macrophage mannose receptor. Demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J. Exp. Med. 172:1990;1785-1794.
26. Gallin E.K., Green S.W., Patchen M.L. Comparative effects of particulate and soluble glucan on macrophages of C3H/HeN and C3H/HeJ mice. Int. J. Immunopharmacol. 14:1992;173-183.
27. Giamis J., Lombard Y., Fonteneau P., Muller C.D., Levy R., Makaya-Kumba M., Lazdins J., Poindron P. Both mannose and β-glucan receptors are involved in phagocytosis of unopsonized, heat-killed Saccharomyces cerevisiae by murine macrophages. J. Leuk. Biol. 54:1993;564-571.
28. 3. Immunology. 63:1988;319-324.
29. Goldman R. Characteristics of the β-glucan receptor of murine macrophages. Exptl. Cell Res. 174:1988;481-490.
30. Hakomori S. Structure and function of sphingoglycolipids in transmembrane signalling and cell-cell interactions. Biochem. Soc. Trans. 21:1993;583-595.
31. Hamuro, J., Chihara, G., 1985. Lentinan, a T-cell-oriented immunopotentiator. Its experimental and clinical applications and possible mechanism of immune modulation. In: Fenichel, R.L., Chirigos, M.A. (Eds.), Immune Modulation Agents and their Mechanisms. Marcel Dekker, New York, pp. 409-436.
32. Hashimoto T., Ohno N., Adachi Y., Yadomae T. Enhanced production of inducible nitric oxide synthase by β-glucans in mice. FEMS Immunol. Med. Microbiol. 19:1997;131-135.
33. Iwabuchi K., Yamamura S., Prinetti A., Handa K., Hakomori S. GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interactionin mouse melanoma B16 cells. J. Biol. Chem. 273:1998;9130-9138.
34. Janusz M.J., Austen K.F., Czop J.K. Isolation of a yeast heptaglucoside that inhibits human monocyte phagocytosis mediated by β-glucan receptors. J. Immunol. 142:1989;959-965.
35. Jimenez-Lucho V., Ginsburg V., Krivan H.C. Cryptococcus neoformans, Candida albicans, and other fungi bind specifically to the glycosphingolipid lactosylceramide (Galβ1-4Glcβ1-1Cer), a possible adhesion receptor for yeasts. Infect. Immun. 58:1990;2085-2090.
36. Kalkhoven E., Wissink S., van der Saag P.T., van der Burg T. Negative interaction between the RelA (p65) subunit of NF-κB and the progesterone receptor. J. Biol. Chem. 271:1996;6217-6224.
37. Kernodle D.S., Gates H., Kaiser A.B. Prophylaxis anti-infective activity of PGG-glucan in a guinea pig mode of staphylococcal wound infection. Antimicrob. Agents Chemother. 42:1998;545-549.
38. Kersh E.N., Shaw A.S., Allen P.M. Fidelity of T cell activation through multistep T cell receptor ζ phosphorylation. Science. 281:1998;572-575.
39. Kniep B., Skubitz K.M. Subcellular localizaiton of glycosphingolipids in human neutrophils. J. Leuk. Biol. 63:1998;83-88.
40. Konopski Z., Smedsrod B., Seljelid R., Eskeland T. A novel immunomodulator soluble aminated β-1,3-D-glucan: Binding characteristics to mouse peritoneal macrophages. Biochim. Biophys. Acta. 1221:1994;61-65.
41. Kunsch C., Ruben S.M., Rosen C.A. Selection of optimal κB/Rel DNA-binding motifs: Interaction of both subunits of NF-κB with DNA is required for trancriptional activation. Mol. Cell Biol. 12:1992;4412-4421.
42. Leonardo M.J., Baltimore D. NF-κB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 58:1989;227-229.
43. Levesque J.-P., Hatzfeld A., Harzfeld J. A method to measure receptor binding of ligands with low affinity. Application to plasma proteins binding assay with hemopoietic cells. Exp. Cell Res. 156:1985;558-562.
44. Liang, J., Melican, D., Cafro, L., Palace, G., Fisette, L., Armstrong, R., Patchen, M.L., 1998. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-Glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Immunopharmacol., in press.
45. Lund-Johansen F., Olweus J., Horejsi V., Skubitz K.M., Thyompson U.S., Vilella R., Symington F.W. Activation of human phagocytes through carbohydrate antigens (CD15, sialyl-CD15, Cds17, and Cdw65). J. Immunol. 148:1992;3221-3229.
46. Mackin W.M., Brunke-Reese D., Gu Y., Crotty C., Fisette L. Enhanced microbicidal activities of human peripheral blood monocytes and neutrophils (PMN) after pre-treatment with PGG-glucan (Betafectin™). FASEB J. 8:1994;A216.
47. McDonald P.P., Bald A., Cassatella M.A. Activation of the NF-κB pathway by inflammatory stimuli in human neutrophils. Blood. 89:1997;3421-3433.
48. Michalek M., Melican D., Brunke-Reese D., Langevin M., Lemerise K., Galbraith W., Patchen M., Mackin W. Activation of rat macrophages by Betafectin® PGG-Glucan requires crosslinking of membrane receptors distinct from complement receptor three. J. Leuk. Biol. 64:1998;337-344.
49. Müller A., Rice P.J., Ensley H.E., Coogan P.S., Kalbfleisch J.H., Kelley J.L., Love E.J., Portera C.A., Ha T., Browder I.W., Williams D.L. Receptor binding and internalization of a water-soluble (1→3)-β-D-glucan biological response modifier in two monocyte/macrophage cell lines. J. Immunol. 156:1996;3418-3425.
50. Muller C.D., Bocchini V., Giamis J., Guerrieri P., Lombard Y., Poindron P. Functional β-glucan receptor expression by a microglial cell line. Res. Immunol. 145:1994;267-275.
51. Obayashi T., Yoshida M., Mori T., Goto H., Yasuoka A., Iwasaki H., Teshima H., Kohno S., Ito A., Yamaguchi H., Shimada K., Kawai T. Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 345:1995;17-20.
52. Onderdonk A.B., Cisneros R.L., Hinkson P., Ostroff G. Anti-infective effect of poly-β1-6-glucotriosyl-β1-3-glucopyranose glucan in vivo. Infect. Immun. 60:1992;1642-1647.
53. Patchen M.L., Liang J., Vaudrain T., Martin T., Melican D., Zhong S., Stewart M., Quesenberry P.J. Mobilization of peripheral blood progenitor cells by Betafectin® PGG-Glucan alone and in combination with granulocyte colony-stimulating factor. Stem. Cells. 16:1998;208-217.
54. Poutsiaka D.D., Mengozzi M., Vannier E., Sinha B., Dinarello C.A. Cross-linking of the β-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production. Blood. 12:1993;3695-3700.
55. 2 release in experimental trauma. J. Trauma. 29:1989;1152-1157.
56. Rasmussen L.-T., Seljelid R. Novel immunomodulators with pronounced in vivo effects caused by stimulation of cytokine release. J. Cell Biochem. 46:1991;60-68.
57. Repo H., Jansson S.-E., Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J. Immunol. Methods. 164:1993;193-202.
58. Repo H., Jansson S.-E., Leirisalo-Repo M. Anticoagulant selection influences flow cytometric determination of CD11b upregulation in vivo and ex vivo. J. Immunol. Methods. 185:1995;65-79.
59. Riboni L., Viani P., Bassi R., Prinetti A., Tettamanti G. The role of sphingolipids in the process of signal transduction. Prog. Lipid Res. 36:1997;153-195.
60. Roecklein J.A., Swartz R.P., Yeager H. Jr. Nonopsonic uptake of Mycobacterium avium complex by human monocytes and alveolar macrophages. J. Lab. Clin. Med. 119:1992;772-781.
61. 3) for β-glucans. Complement. 4:1987;61-74.
62. Ruocco M.R., Chen X., Ambrosino C., Dragonetti E., Liu W., Mallardo M., DeFalco G., Palmieri C., Franzoso G., Quinto I., Venuta S., Scala G. Regulation of HIV-1 long terminal repeats by interaction of C/EBP (NF-IL6) and NF-κB/Rel transcription factors. J. Biol. Chem. 271:1996;22479-22486.
63. Sakurai T., Suzuki I., Kinoshita A., Oikawa S., Masuda A., Ohsawa M., Yodomae T. Effect of intraperitoneally administered β-1,3-glucan, SSG, obtained from Sclerotinia sclerotiorum IFO 9395 on the functions of murine alveolar macrophages. Chem. Pharm. Bull. 39:1991;214-217.
64. Sandberg A.L., Rhul S., Joralmon R.A., Brennan J., Sutphin M.J., Cisar J.O. Putative glycoprotein and glycolipid polymorphonuclear leukocyte receptors for the Actinomyces naeslundii WVU45 fimbrial lectin. Infec. Immun. 63:1995;2625-2631.
65. Sherwood E.R., Williams D.L., McNamee R.B., Jones E.L., Browder I.W., Di Luzio N.R. Enhancement of interleukin-1 and interleukin-2 production by soluble glucan. Int. J. Immunopharmacol. 9:1987;361-367.
66. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol. 10:1994;405-455.
67. Somogyi M. Notes on sugar determination. J. Biol. Chem. 195:1952;19-23.
68. Song Y., Withers D.A., Hakomori S. Globoside-dependent adhesion of huamn embryonal carcinoma cells, based on carbohydrate-carbohydrate interaction, initiates signal transduction and induces enhanced activity of transcription factors AP1 and CREB. J. Biol. Chem. 273:1998;2517-2525.
69. Stashenko P., Wang C.Y., Riley E., Wu Y., Ostroff G., Niederman R. Reduction of infection-stimulated periapical bone resorption by the biological response modifier PGG Glucan. J. Dent. Res. 74:1995;323-330.
70. Stein B., Cogswell P.C., Baldwin A.S. Jr. Functional and physical associations between NF-κB and C/EBP family members: a rel domain-bzip interaction. Mol. Cell. Biol. 13:1993;3964-3974.
71. Stokes R.W., Haidl I.D., Jefferies W.A., Speert D.P. Mycobacteria-macrophage interactions: macrophage phenotype determines the nonopsonic binding of mycobacterium tuberculosis to murine macrophages. J. Immunol. 151:1993;7067-7076.
72. Stone, B.A., Clarke, A.E., 1992. (1→3)-β-glucans and animal defense mechanisms. In: Stone, B.A., Clarke, A.E. (Eds.), Chemistry and Biology of (1→3)-β-glucans. Australia: La Trobe University Press, pp. 525-564.
73. Stromberg N., Ryd M., Lindberg A.A., Karlsson K.-A. Studies on the binding of bacteria to glycolipids. Two species of propionibacterium apparently recognize separate epitopes on lacots of lactosylceramide. FEB. 232:1988;193-198.
74. Symington F.W. Cdw17: A neutrophil glycolipid antigen regulated by activation. J. Immunol. 142:1989;2784-2790.
75. Symington F.W., Bernstein I.D., Hakomori S. Monoclonal antibody specific for lactosylceramide. J. Biol. Chem. 259:1984;6008-6012.
76. Symington F.W., Murray W.A., Bearman S.I., Hakomori S. Intracellular localization of lactosylceramide, the major human neutrophil glycosphingolipid. J. Biol. Chem. 262:1987;11356-113663.
77. Szabo T., Kadish J.L., Czop J.K. Biochemical properties of the ligand-binding 20-kDa subunit of the β-glucan receptors on human mononuclear phagocytes. J. Biol. Chem. 270:1995;2145-2151.
78. Tagteishi T., Ohno N., Adachi Y., Yadomae T. Increases in hematopoietic responses caused by β-glucans in mice. Biosci. Biotech. Biochem. 61:1997;1348-1353.
79. Thornton B.P., Vetvicka V., Pitman M., Goldman R.C., Ross G.D. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1996;1235-1246.
80. Torigoe C., Inman J.K., Metzger H. An unusual mechanism for ligand antagonism. Science. 281:1998;568-572.
81. Ulevitch R.J., Tobias P.S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Ann. Rev. Immunol. 13:1995;437-457.
82. 2, Mac-1). Indirect effects of an ARG-GLY-ASP (RGD) sequence. J. Immunol. 151:1993;3324-3336.
83. Vetvicka V., Thornton B.P., Ross G.D. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98:1996;50-61.
84. Vetvicka V., Thornton B.P., Wieman T.J., Ross G.D. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Immunol. 159:1997;599-605.
85. Wakshull E., Correira H., Sidloski T. Synergistic stimulation of myeloid progenitor cell proliferation by a novel β-glucan and rmGM-CSF. J. Cell Biochem. 18A:1994;22. Supplement.
86. Wakshull E., Lindermuth J., Zimmerman J. Characterization of PGG-Glucan binding to a β-glucan receptor on human leukocytes. FASEB J. 10:1996;A1338.
87. Wakshull E., Zimmerman J., Adams D., Michalek M. Characterization of PGG-Glucan binding to and signaling through the leukocyte soluble β-glucan receptor. J. Leuk. Biol. Supplement:1996;59.
88. Ziegler-Heitbrock H.W.L., Frankenberger M., Wedel A. Tolerance to lipopolysaccharide in human blood monocytes. Immunobiol. 193:1995;217-223.
89. Zimmerman J., Lindermuth J., Fish P.A., Palace G.P., Stevenson T.T., DeMong D.E. A novel carbohydrate-glycosphingolipid interaction between a β-(1-3)-glucan immunomodulator and lactosylceramide of human leukocytes. J. Biol. Chem. 273:1998;22014-22020.